Projects

Minakem’s High-Containment Production Facility, Louvain-la-Neuve, Belgium

In the second half of 2018, Minakem opened a new high-containment production facility in Louvain-la-Neuve, Belgium.

Project Type

High-containment production facility

Location

Louvain-la-Neuve, Belgium

Opened

2018

Owner

Minafin Group

Expand

In the second half of 2018, Minakem opened a new high-containment production facility in Louvain-la-Neuve, Belgium.

The new facility enables Minakem to economically develop and produce bulk quantities of highly potent compounds. It also extends the company’s capability to manufacture highly potent active pharmaceutical ingredients (API) and antibody drug conjugates (ADC) from small-scale to full-scale good manufacturing practice (GMP) batch releases.

The facility reached the final qualification phase in June 2018. It employs 20 scientists and 17 quality check personnel.

Minakem is a contract development and manufacturing organisation (CDMO) division of chemical production company Minafin.

Location of Minakem’s new high-containment production facility

The new facility is located in Minakem’s Louvain-la-Neuve site in Belgium, which operates as a separate entity named Minakem High Potent.

It is in close proximity to two of Minakem’s existing API sites in Louvain-la-Neuve.

Minakem’s high-containment facility details

The new production facility is equipped with a high-pressure preparative chromatography system that permits the isolation and purification of target molecules at different scales ranging from milligrams to hundreds of grams.

“The new Belgian high-containment facility comprises six production lines that are equipped with stainless steel and hastelloy jacketed reactors.”

The plant also features a 130m² laboratory that will engage in the development of GMP kilo-lab manufacturing and is equipped with state-of-the-art equipment, including nine fume hoods, new generation glove bins for dry powder handling and high-efficiency particulate air (HEPA) air filters.

Minakem’s high-performance active pharmaceutical ingredient (HPAPI) production occurs with an occupational exposure limit (OEL) level lower than 0.1µg/m3.8h. The new facility also produces antibody-drug conjugate (ADC) toxins at 10ng/m³ levels.

Production equipment and technology details

Minakem’s new high-containment facility comprises six production lines that are equipped with stainless steel and hastelloy jacketed reactors varying from 5l to 1,600l in size.

The facility is equipped with different kinds of isolation equipment for batch sizes ranging from 100g to 100kg. They are designed for the safe handling of potent compounds.

The high-pressure chromatography (HPLC) system installed at the facility includes a 50mm column Hipersep® Prep-HPLC system and 300mm column HPLC system capability. It enables Minakem to manufacture pharmaceutical ingredients that require a high level of purity.

Marketing commentary on Minakem

Founded in 2004, Minakem is an affiliate of the Minafin Group and headquartered in France. It specialises in the manufacture of fine chemicals, API, key intermediates and building blocks for pharmaceutical companies.

Minakem employs more than 450 people at its three facilities in Dunkirk and Beuvry-la-Forêt in France and Louvain-la-Neuve in Belgium. The company gained ownership of the Louvain-la-Neuve site through the acquisition of Ajinomoto OmniChem, which enabled Minakem to expand its pharmaceutical services and fortify the development of its market share.

All of the company’s facilities are engaged in the production of small, medium and large volumes of complex, regulated intermediates and API for the pharmaceutical and life science industries. The facilities are equipped with technologies such as complex multi-step synthesis, halogenation chemistry and steroid chemistry.

Related Projects